Eyepoint Pharmaceuticals (EYPT) Competitors

$12.93 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$12.92 -0.01 (-0.08%)

As of 05/22/2026 07:21 PM Eastern

EYPT vs. VNT, TXG, AEHR, ALMR, and ALNT

Should you buy Eyepoint Pharmaceuticals stock or one of its competitors? MarketBeat compares Eyepoint Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eyepoint Pharmaceuticals include Vontier (VNT), 10x Genomics (TXG), Aehr Test Systems (AEHR), Alamar Biosciences (ALMR), and Allient (ALNT). These companies are all part of the "measuring and control equipment" industry.

How does Eyepoint Pharmaceuticals compare to Vontier?

Vontier (NYSE:VNT) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both measuring and control equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Vontier has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Vontier has a net margin of 13.37% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Vontier's return on equity of 37.88% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vontier	13.37%	37.88%	10.90%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

In the previous week, Vontier had 3 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 5 mentions for Vontier and 2 mentions for Eyepoint Pharmaceuticals. Vontier's average media sentiment score of 0.96 beat Eyepoint Pharmaceuticals' score of 0.00 indicating that Vontier is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vontier	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vontier has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Vontier, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vontier	$3.08B	1.36	$406.10M	$2.83	10.48
Eyepoint Pharmaceuticals	$31.37M	34.56	-$231.96M	-$3.50	N/A

95.8% of Vontier shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 1.1% of Vontier shares are held by insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vontier presently has a consensus price target of $42.38, suggesting a potential upside of 42.91%. Eyepoint Pharmaceuticals has a consensus price target of $31.80, suggesting a potential upside of 145.94%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Vontier.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vontier	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Vontier beats Eyepoint Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

10x Genomics has a net margin of -3.55% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. 10x Genomics' return on equity of -2.86% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

10x Genomics has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

In the previous week, 10x Genomics and 10x Genomics both had 2 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.00 beat 10x Genomics' score of -0.05 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10x Genomics has higher revenue and earnings than Eyepoint Pharmaceuticals. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	4.68	-$43.54M	-$0.17	N/A
Eyepoint Pharmaceuticals	$31.37M	34.56	-$231.96M	-$3.50	N/A

10x Genomics currently has a consensus target price of $23.17, suggesting a potential downside of 2.17%. Eyepoint Pharmaceuticals has a consensus target price of $31.80, suggesting a potential upside of 145.94%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

10x Genomics beats Eyepoint Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Aehr Test Systems (NASDAQ:AEHR) are both measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Aehr Test Systems has higher revenue and earnings than Eyepoint Pharmaceuticals. Aehr Test Systems is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	34.56	-$231.96M	-$3.50	N/A
Aehr Test Systems	$58.97M	50.68	-$3.91M	-$0.38	N/A

Eyepoint Pharmaceuticals presently has a consensus price target of $31.80, suggesting a potential upside of 145.94%. Aehr Test Systems has a consensus price target of $68.00, suggesting a potential downside of 28.44%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Aehr Test Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aehr Test Systems	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Aehr Test Systems shares are owned by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 6.8% of Aehr Test Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Aehr Test Systems has a beta of 3.26, meaning that its share price is 226% more volatile than the broader market.

Aehr Test Systems has a net margin of -25.23% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Aehr Test Systems' return on equity of -7.15% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Aehr Test Systems	-25.23%	-7.15%	-6.15%

In the previous week, Aehr Test Systems had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Aehr Test Systems and 2 mentions for Eyepoint Pharmaceuticals. Aehr Test Systems' average media sentiment score of 0.73 beat Eyepoint Pharmaceuticals' score of 0.00 indicating that Aehr Test Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aehr Test Systems	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aehr Test Systems beats Eyepoint Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alamar Biosciences presently has a consensus target price of $30.00, indicating a potential upside of 49.55%. Eyepoint Pharmaceuticals has a consensus target price of $31.80, indicating a potential upside of 145.94%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Alamar Biosciences has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Alamar Biosciences' return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Alamar Biosciences. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.00 equaled Eyepoint Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$87.16M	15.95	N/A	N/A	N/A
Eyepoint Pharmaceuticals	$31.37M	34.56	-$231.96M	-$3.50	N/A

Summary

Eyepoint Pharmaceuticals beats Alamar Biosciences on 7 of the 11 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Allient?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Allient (NASDAQ:ALNT) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Allient has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	34.56	-$231.96M	-$3.50	N/A
Allient	$554.48M	1.94	$22.03M	$1.43	44.31

Eyepoint Pharmaceuticals presently has a consensus price target of $31.80, indicating a potential upside of 145.94%. Allient has a consensus price target of $72.25, indicating a potential upside of 14.01%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Allient	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 61.6% of Allient shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Allient shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Allient has a net margin of 4.25% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Allient's return on equity of 12.47% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Allient	4.25%	12.47%	6.37%

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Allient. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Allient. Allient's average media sentiment score of 0.40 beat Eyepoint Pharmaceuticals' score of 0.00 indicating that Allient is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allient	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Allient has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Summary

Allient beats Eyepoint Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EYPT vs. The Competition

Export

Metric	Eyepoint Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.08B	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-3.69	18.74	21.21	25.65
Price / Sales	34.56	323.98	554.38	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	4.70	7.09	10.37	7.14
Net Income	-$231.96M	$24.45M	$3.57B	$335.98M
7 Day Performance	9.39%	6.38%	6.40%	4.15%
1 Month Performance	-6.47%	2.43%	3.53%	2.54%
1 Year Performance	127.64%	62.98%	34.04%	35.06%

Eyepoint Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EYPT Eyepoint Pharmaceuticals	2.3815 of 5 stars	$12.93 flat	$31.80 +145.9%	+127.6%	$1.08B	$31.37M	N/A	120
VNT Vontier	4.649 of 5 stars	$28.09 +0.4%	$42.38 +50.9%	-16.0%	$3.96B	$3.08B	9.93	7,800	Dividend Announcement Buyback Announcement
TXG 10x Genomics	1.4523 of 5 stars	$22.22 +3.6%	$23.17 +4.3%	+189.8%	$2.82B	$642.82M	N/A	1,240	Gap Up
AEHR Aehr Test Systems	2.0431 of 5 stars	$82.68 -1.1%	$68.00 -17.8%	+973.7%	$2.58B	$58.97M	N/A	90	Gap Down
ALMR Alamar Biosciences	4.3324 of 5 stars	$20.57 -1.4%	$30.00 +45.8%	N/A	$1.43B	$87.16M	N/A	222	Quiet Period Expiration Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EYPT) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. VNT, TXG, AEHR, ALMR, and ALNT

How does Eyepoint Pharmaceuticals compare to Vontier?

Summary

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

Summary

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Summary

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Summary

How does Eyepoint Pharmaceuticals compare to Allient?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. VNT, TXG, AEHR, ALMR, and ALNT

How does Eyepoint Pharmaceuticals compare to Vontier?

Which has more risk & volatility, VNT or EYPT?

Is VNT or EYPT more profitable?

Does the media favor VNT or EYPT?

Which has better earnings and valuation, VNT or EYPT?

Do insiders and institutionals have more ownership in VNT or EYPT?

Do analysts prefer VNT or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

Is TXG or EYPT more profitable?

Do insiders & institutionals hold more shares of TXG or EYPT?

Which has more volatility & risk, TXG or EYPT?

Does the media favor TXG or EYPT?

Which has preferable valuation and earnings, TXG or EYPT?

Do analysts rate TXG or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Which has stronger earnings & valuation, EYPT or AEHR?

Do analysts rate EYPT or AEHR?

Do institutionals and insiders hold more shares of EYPT or AEHR?

Which has more volatility and risk, EYPT or AEHR?

Is EYPT or AEHR more profitable?

Does the media favor EYPT or AEHR?

Summary

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Do insiders and institutionals hold more shares of ALMR or EYPT?

Do analysts rate ALMR or EYPT?

Is ALMR or EYPT more profitable?

Does the media refer more to ALMR or EYPT?

Which has higher earnings and valuation, ALMR or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Allient?

Which has better earnings & valuation, EYPT or ALNT?

Do analysts rate EYPT or ALNT?

Do institutionals & insiders believe in EYPT or ALNT?

Is EYPT or ALNT more profitable?

Does the media refer more to EYPT or ALNT?

Which has more volatility & risk, EYPT or ALNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools